Cryo Cell International (CCEL) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 revenue reached $32.0 million, up from $31.3 million year-over-year.

• Net income was $402,000 ($0.05 per share) versus a net loss of $9.5 million ($1.14 per share) in fiscal 2023.

• Prior year loss driven by $13.1 million Duke License Agreement impairment and $3.7 million public bank inventory impairment.

Financial highlights

• Processing and storage fee revenue was $31.6 million, product revenue $68,000, and public banking revenue $367,000 for fiscal 2024.

• Realized and unrealized gains on marketable securities totaled $1.1 million, up from $51,000 year-over-year.

• Income tax expense was $2.4 million, with $1.3 million due to a change in Florida revenue apportionment methodology.

Outlook and guidance

• Reduced expenditures related to the Duke License Agreement are expected in 2025, but higher legal expenses are anticipated.